It’s just one deal, but genomics companies with exposure to in vivo gene editing may be getting a much-needed boost after blue-chip pharmaceuticals company Pfizer (NYSE:PFE) announced a related agreement with Beam Therapeutics (NASDAQ:BEAM) on Monday. Among exchange traded funds with leverage...